Helping Your Research
Targeted Content for Cancer Biology
The GeoMx Immune Pathways Panel is designed for targeted profiling of the tumor, tumor microenvironment, and tumor immune status.
Profile up to 96 RNA targets with spatial resolution from a single tissue section using the GeoMx Digital Spatial Profiler (DSP).
How it Works
The Immune Pathways panel contains 84 targets plus controls designed for broad coverage of the tumor and tumor microenvironment. GeoMx RNA assays contain in situ hybridization (ISH) probes conjugated to unique DNA indexing-oligonucleotides via a UV-photocleavable linker. After region of interest (ROI) selection on GeoMx DSP and UV cleavage of the oligonucleotides, each DNA oligonucleotide is recognized by a unique Reporter probe that contains a fluorescent barcode. Reporter probes are imaged and counted by the nCounter® Analysis System to provide a direct, digital readout of spatially resolved RNA expression.
- Curated content designed for immuno-oncology research
- Includes tumor and tumor microenvironment coverage plus the Tumor Inflammation Signature (TIS)
- Pre-validated in multiplex format for use in human FFPE or fresh frozen tissue
- Compatible with RNAscope® and antibody morphology markers for tissue imaging
- Customizable with up to 10 additional targets of interest
- For use with nCounter readout and compatible with DSP Data Center
Curated Content for Immuno-Oncology
The GeoMx Immune Pathways panel is designed to profile key aspects of the tumor and tumor microenvironment biology.
- Profile the global immune response
- Assess microenvironment immune activity
- Quantify tumor reactivity
- Measure the 18-gene Tumor Inflammation Signature known to be associated with response to PD-1/PD-L1 inhibitor pathway blockade
Accompanying Morphology Marker Kits are available for tissue visualization and ROI selection.
Activin A-mediated polarization of cancer-associated fibroblasts and macrophages confers resistance to checkpoint immunotherapy in skin cancer
Purpose: Cemiplimab is approved for the treatment of locally advanced basal cell carcinomas (BCCs), however with mitigated results. We sought to interrogate the cellular and molecular transcriptional reprogramming underlying BCC resistance to immunotherapy.
Two Cases of Severe Pulmonary Toxicity from Highly Active Mesothelin-Directed CAR T Cells
Multiple clinical studies have treated mesothelin (MSLN)-positive solid tumors by administering MSLN-directed chimeric antigen receptor (CAR) T cells. Although these products are generally safe, efficacy is limited.
Harnessing the potential of spatial multiomics: a timely opportunity
In a recent publication in Nature,1 Zhang et al. have developed spatial ATAC-RNA-seq and spatial CUT&Tag-RNA-seq as innovative tools that enable the high-resolution mapping of epigenetic and transcriptomic features in cells from frozen tissue sections.
Request a Quote
Contact our helpful experts and we’ll be in touch soon.